Clinician Scientist in Leukemia

项目概要/摘要 这个项目是为了支持申请人作为临床科学家在白血病在华盛顿大学 医学院/Siteman癌症中心支持NCI资助的临床研究。作为医学总监， 临床研究，申请人将通过1） 提高运营效率，2）扩展计划能力，3）确保方案合规性， 实现最高质量的临床试验，以改善癌症患者的生活。 申请人还将作为白血病联合主席，为NCI资助的研究提供科学领导。 肿瘤临床试验联盟委员会和myeloMATCH的老年AML临床篮， 国家癌症研究所骨髓恶性肿瘤精准医学计划联盟的白血病委员会将 继续进行改变实践的治疗试验，并进一步了解 白血病及其治疗此外，委员会将通过增加 代表性不足的少数群体的增加和评估健康的社会决定因素的影响。 在患有AML的老年人中，myeloMATCH将测试靶向治疗与低甲基化 药物和维奈托克，以提高缓解率，并验证流式细胞术的预后意义- 基于可测量的残留疾病。将在治疗期间实施伴随老年评估 研究以验证预测治疗耐受性和获益的措施。

PROJECT SUMMARY / ABSTRACT This project is intended to support the applicant as a clinician-scientist in leukemia at Washington University School of Medicine / Siteman Cancer Center supporting NCI-funded clinical research. As Medical Director for Clinical Research, the applicant will support the implementation of clinical research at the institution by 1) improving operational efficiency, 2) expanding program capabilities, and 3) ensuring protocol compliance to achieve the highest quality conduct of clinical trials that can improve the lives of patients with cancer. The applicant will also provide scientific leadership to NCI-funded research as co-chair of the Leukemia Committee of the Alliance for Clinical Trials in Oncology and the Older AML Clinical Basket for myeloMATCH, the NCI Precision Medicine Initiative in myeloid malignancies. The Leukemia Committee of the Alliance will continue to conduct practice-changing treatment trials and further our understanding of the biological basis of leukemia and its treatment. In addition, the Committee will address health disparities in leukemia by increasing the accrual of underrepresented minorities and assessing the impact of social determinants of health. In older adults with AML, myeloMATCH will test the combination of targeted therapies with hypomethylating agents and venetoclax to improve remission rates and validate the prognostic significance of flow cytometry- based measurable residual disease. A companion geriatric assessment will be implemented across treatment studies to validate measures that predict treatment tolerance and benefit.